Retina Implant has seen some results from its first human clinical trial, with 11 patients who lost their sight due to retinitis pigmentosa (RP) taking part.
Following the subretinal implant, a few of the patients were able to see objects and shapes with such clarity they could combine letters to form words and recognise foreign objects.
RP is one of the most common forms of inherited retinal degenerations and affects around 200,000 people in the world.
"During the course of our first trial, we learned a great deal between our first and last patient, especially from patient ten to 11," commented Dr Walter Wrobel, president and chief executive officer of Retina Implant.
He noted that the research discovered that placing the chip in the macular region provided superior clinical outcomes.
by Martin Burns